2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10813
    ZLIRTLHEWY
    ZLIRTLHEWY is a potent peptide CD47/SIRPα interaction inhibitor. ZLIRTLHEWY is promising for research of cancers.
    ZLIRTLHEWY
  • HY-P1081A
    Acetyl-Calpastatin(184-210)(human) TFA
    Acetyl-Calpastatin(184-210)(human) TFA is a potent, selective and reversible calpain inhibitor with Ki values of 0.2 nM and 6 μM for µ-calpain and cathepsin L, respectively.
    Acetyl-Calpastatin(184-210)(human) TFA
  • HY-P10827
    PIC1 PA 1356469-36-7
    PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM.
    PIC1 PA
  • HY-P10828
    MAPI 1260620-30-1
    MAPI is a polypeptide irreversible 3C cysteine protease (SV3CP) inhibitor. MAPI inhibits SV3CP by covalently binding its C-terminal Michael-acceptor extension to the active site thiol of SV3CP Cys 139. MAPI is promising for research of noroviruses infection.
    MAPI
  • HY-P10837
    LAG-3 cyclic peptide inhibitor 12
    LAG-3 cyclic peptide inhibitor 12 (Cyclic peptide 12) is an inhibitor of LAG-3 with an IC50 value of 4.45 μM and a Ki value of 2.66 µM.
    LAG-3 cyclic peptide inhibitor 12
  • HY-P10838
    PL120131
    PL120131 is a PD-1/PD-L1 inhibitory peptide that can interfere with the interaction of PD-1/PD-L1 by binding to PD-1. PL120131 is capable of inhibiting the PD-1-mediated apoptotic signaling pathway, protecting Jurkat cells and primary lymphocytes from apoptosis. PL120131 aids in the antitumor activity of cytotoxic T lymphocytes (CTLs).
    PL120131
  • HY-P10839
    NBD peptide 371915-62-7
    NBD peptide inhibits NF-κB signaling pathway through inhibition of the NEMO-IKK complex combination. NBD peptide exhibits anti-inflammatory efficacy through block of pro-inflammatory cytokines production. NBD peptide exhibits immunosuppressive activity through regulation of immune cells. NBD peptide enhances its transmembrane ability by combining with cell-penetrating peptide HIV-TAT.
    NBD peptide
  • HY-P10840
    Tkip 716361-65-8
    Tkip is a JAK2 specific inhibitor. Tkip can bind the JAK2 autophosphorylation site, inhibit the JAK2 autophosphorylation and the phosphorylation of the IFN-γ receptor subunit IFNGR-1. Tkip inhibits the antiviral activity of IFN-γ and the expression of MHC Class I molecules. Tkip can be used to study the IFN-γ signaling pathway.
    Tkip
  • HY-P10842
    d-GLP-2 E33A
    d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC50 of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases.
    d-GLP-2 E33A
  • HY-P10850
    PIYLGGVFQ
    PIYLGGVFQ is a peptide inhibitor for TNF-α. PIYLGGVFQ inhibits TNF-α-mediated apoptosis, NF-κB nuclear translocation and activation. PIYLGGVFQ exhibits anti-arthritic activity in the CIA mouse model.
    PIYLGGVFQ
  • HY-P10851
    HVEM(14-39)
    HVEM(14-39) is a B- and T-lymphocyte attenuator (BTLA) peptide inhibitor. HVEM (14-39) can be combined with BTLA with a KD of 0.102 μM. HVEM(14-39) enhances the activation and proliferation of T cells by regulating the expression of BTLA and HVEM in T cells, and promotes the transformation of cells into effector memory T cells. HVEM(14-39) inhibits tumor cell proliferation and promotes late apoptosis. HVEM(14-39) has immunomodulatory effects and can be used in the study of cancer.
    HVEM(14-39)
  • HY-P10854
    TAT-N15 2415370-74-8
    TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke.
    TAT-N15
  • HY-P10868
    Pegtarazimod 2056232-82-5
    Pegtarazimod (RLS-0071) is an inhibitor for Complement system via classical and lectin pathways. Pegtarazimod inhibits myeloperoxidase (MPO), reduces ROS generation. Pegtarazimod reduces the formation of neutrophil extracellular traps (NETs). Pegtarazimod exhibits anti-inflammatory activity and can be used in research of acute graft-versus-host disease.
    Pegtarazimod
  • HY-P10882
    Gletimbetasin 921944-96-9
    Gletimbetasin is a thymosin β4 analog with anti-inflammatory activity.
    Gletimbetasin
  • HY-P10889
    CNI103 2366279-86-7
    CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (KD=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases.
    CNI103
  • HY-P10897
    SjDX5-271 2767993-76-8
    SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury.
    SjDX5-271
  • HY-P10914
    D-CopA3 1426227-11-3
    D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC50=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models.
    D-CopA3
  • HY-P10935
    Amilo-5MER 1860001-61-1
    Amilo-5MER (5-MP) is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER is promising for research of autoimmune diseases and chronic inflammatory diseases.
    Amilo-5MER
  • HY-P10936
    AQP4 (201-220) 2104700-59-4
    AQP4 (201-220) is an encephalitogenic epitope of AQP-4. AQP4 (201-220) can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica.
    AQP4 (201-220)
  • HY-P10937
    AQP4 (205-215) 2891466-35-4
    AQP4 (205-215) is a fragment of Aquaporin-4 (AQP4). AQP4 is a neuromyelitis optica autoantigen that is upregulated and presented in B cells after engagement of CD40. AQP4 is associated with autoimmune inflammatory diseases of the central nervous system (CNS), neuromyelitis optica (NMO).
    AQP4 (205-215)
Cat. No. Product Name / Synonyms Application Reactivity